Corbus Pharmaceuticals Holdings (LTS:0SZI) Preferred Dividends: $0.00 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0SZI Corbus Pharmaceuticals Holdings Inc LTS:0SZI
44 GF Score
Price $9.93
GF Value $1.01
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Corbus Pharmaceuticals Holdings Preferred Dividends?

Corbus Pharmaceuticals Holdings LTS:0SZI +3.03% 44 Preferred Dividends is $0.00 Mil as of Jun. 2026. GuruFocus rates LTS:0SZI with a GF Score™ of 44/100 and a GF Value™ of $1.01 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Preferred dividend is a dividend that is accrued and paid on a company's preferred shares. Corbus Pharmaceuticals Holdings's preferred dividends for the three months ended in Jun. 2026 was $0.00 Mil. Its preferred dividends for the trailing twelve months (TTM) ended in Jun. 2026 was $0.00 Mil.

Corbus Pharmaceuticals Holdings  (LTS:0SZI) Preferred Dividends Explanation

In the event that a company is unable to pay all dividends, claims to preferred dividends take precedence over claims to dividends that are paid on common shares.

Preferred Dividends for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corbus Pharmaceuticals Holdings Preferred Dividends Historical Data

* Premium members only.

The historical data trend for Corbus Pharmaceuticals Holdings's Preferred Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corbus Pharmaceuticals Holdings Preferred Dividends Chart

Corbus Pharmaceuticals Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Preferred Dividends
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Corbus Pharmaceuticals Holdings Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Preferred Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
LTS:0SZI
44GF Score
Corbus Pharmaceuticals Holdings Inc LTS:0SZI
Preferred Dividends is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Corbus Pharmaceuticals Holdings Preferred Dividends Calculation

A dividend that is accrued and paid on a company's preferred shares.

Frequently Asked Questions Learn more about Preferred Dividends →
What does a Preferred Dividends of $0.00 Mil mean?
Corbus Pharmaceuticals Holdings (LTS:0SZI) has a Preferred Dividends of $0.00 Mil as of Jun. 2026. Preferred Dividends is the total amount a company pays out as dividends on its preferred shares. View historical data on Corbus Pharmaceuticals Holdings and its competitors.
Is Corbus Pharmaceuticals Holdings' Preferred Dividends too high?
Corbus Pharmaceuticals Holdings' current Preferred Dividends is $0.00 Mil. Overall, Corbus Pharmaceuticals Holdings has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Corbus Pharmaceuticals Holdings' Preferred Dividends compare to OKUR and HUMA?
Corbus Pharmaceuticals Holdings' Preferred Dividends of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Preferred Dividends for a Biotechnology company?
A good Preferred Dividends depends on the Biotechnology industry context. However, Preferred Dividends should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Preferred Dividends mean?
A high Preferred Dividends can signal that a stock is expensive relative to its fundamentals. Preferred Dividends is the total amount a company pays out as dividends on its preferred shares. View historical data on Corbus Pharmaceuticals Holdings and its competitors. Corbus Pharmaceuticals Holdings's current Preferred Dividends is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corbus Pharmaceuticals Holdings stock overvalued right now?
Based on GuruFocus' analysis, Corbus Pharmaceuticals Holdings (LTS:0SZI) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.01, compared to a current price of $9.93 — trading 883.4% above its estimated fair value. The current Preferred Dividends is $0.00 Mil. Corbus Pharmaceuticals Holdings' overall GF Score™ is 44/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Preferred Dividends calculated?
Preferred Dividends is calculated from a company's financial statements. For Corbus Pharmaceuticals Holdings (LTS:0SZI), the current Preferred Dividends is $0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Corbus Pharmaceuticals Holdings (LTS:0SZI) Overvalued in 2026?

Based on GuruFocus' analysis, Corbus Pharmaceuticals Holdings stock appears to be overvalued. The current stock price of $9.93 is trading 883.4% above its estimated GF Value™ of $1.01. GuruFocus considers Corbus Pharmaceuticals Holdings to be Significantly Overvalued.

Key valuation signals for LTS:0SZI:

  • Preferred Dividends: $0.00 Mil
  • GF Value™: $1.01 vs. price of $9.93 (883.4% above fair value)
  • GF Score™: 44/100 with 2 warning signs

No single metric tells the full story. See the LTS:0SZI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Corbus Pharmaceuticals Holdings Business Description

Other Exchanges CRBP:USA3371:Germany
Address 500 River Ridge Drive, Norwood, MA, USA, 02062
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
44GF Score

Get the complete analysis for LTS:0SZI

Preferred Dividends is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.93
Price
$1.01
GF Value